Acute low back pain as infusion-related reaction to monoclonal antibodies

Frontiers in Oncology

Oncology

Pawel Majenka¹  Jessica Hassel¹  Alexander Enk¹  Carmen Loquai²  Tilman Schöning³ 

[1] Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany;Department of Dermatology, University Medical Center Mainz, Mainz, Germany;Department of Pharmacy, University Hospital Heidelberg, Heidelberg, Germany;

关键词: skin cancer;    immunotherapy;    PD-1/PD-L1 inhibitors;    infusion-related reactions;    low back pain;   

DOI  :  10.3389/fonc.2023.1161818

 received in 2023-06-02, accepted in 2023-09-20,  发布年份 2023

来源: Frontiers

【 摘 要 】

Monoclonal antibodies, such as PD-1 inhibitors, are increasingly used in various cancers. Acute low back pain as infusion-related reaction (IRR) to monoclonal antibodies is poorly described. We report a bicentric series of 10 cases of acute low back pain due to administration of monoclonal antibodies directed against PD-1/PD-L1 for skin cancer treatment in patients treated at University Hospital Heidelberg and University Medical Center Mainz (Germany). The management of IRR symptoms was immediate interruption of infusion and analgesia leading to quick improvement and complete symptom relief in all patients. Our findings suggest that the risk of developing low back pain as IRR is depending on the concentration of the administered drug. Low back pain as IRR can be managed by early interruption of infusion and by decreasing the infusion rate or concentration in following administrations.

【 授权许可】

Unknown   
Copyright © 2023 Majenka, Loquai, Schöning, Enk and Hassel